



WuXi AppTec

2025 J.P. Morgan Healthcare Conference

January 15, 2025



603259.SH / 2359.HK

Forward-Looking Statements

This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not historical facts, but instead are predictions about future events based on our beliefs, development strategy, business plan as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings or production capacity, our ability to reach the scale of our production capacity expansion plans, our ability to protect our clients’ intellectual property, competition, unforeseeable change of international policy, the impact of emergencies and other force majeure. Our forward-looking statements do not constitute any profit forecast by our management nor a undertaking by WuXi AppTec Co., Ltd. (“WuXi AppTec” or the “Company”) to our investors. **ACCORDINGLY, YOU ARE STRONGLY CAUTIONED THAT RELIANCE ON ANY FORWARD-LOOKING STATEMENTS INVOLVES KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES.** All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement or information in this presentation to reflect future events or circumstances, except as required under applicable law.

Non-IFRS Financial Measures

We provide non-IFRS gross profit and non-IFRS net profit attributable to the owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses and amortization of acquired intangible assets from merger and acquisition, non-financial assets impairment, etc. We also provide adjusted non-IFRS net profit attributable to the owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither of the above is required by, or presented in accordance with IFRS.

We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such non-IFRS financial measures, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

Intellectual Property

All intellectual property rights and other rights pertaining to the information and materials presented in the presentation are owned by WuXi AppTec. Audio recording, video recording or disclosure of such materials by any means without the prior consent of WuXi AppTec is prohibited.

Disclaimer

This presentation is for information purposes only and does not constitute a recommendation regarding any securities of the Company. This presentation does not intend to provide a complete statement relating to the Company, its securities, or any relevant matters herein that a recipient may need in order to evaluate the Company. For relevant information, please refer to the Company’s disclosure documents and information on the Shanghai Stock Exchange, the Stock Exchange of Hong Kong Limited and the Company’s website.



01

Company Overview

02

Business Highlights

03

Financial Performance

04


Company Outlook

1. Company Overview

With Customers as our Top Priority, Demand for Our Integrated CRDMO Services Continues to Grow Despite External Challenges

Our Vision

“Every drug can be made and every disease can be treated” through building the open-access platform with the most comprehensive capabilities and technologies in the global healthcare industry



Focused on Delivering Value to Customers as Leading Global CRDMO Company



6,000+

Active Customers¹



38,000+

Total Employees¹



32

Global Sites in 9 Countries¹



>3,300

of Molecules in Small
Molecule CDMO Pipeline¹



18%

of Small Molecule New Drugs
Approved by FDA 2018-2024



41,000L

Solid Phase Peptide Synthesizer
Capacity by end of 2024

Continuously Enhance Capabilities and Capacity to Support Future Growth

Accelerate Global CRDMO Capacity Expansion to Better Meet Growing Customer Demand



Actively Promoting Sustainability and Enhancing Global ESG Leadership

Consecutive Four Years' MSCI "AA" Rating and S&P Global DJSI Member; Improved to EcoVadis "Gold" Rating in 2024



Consecutive "AA" ratings
in 2021-2024



Improved to "Gold" rating
by EcoVadis in 2024

Member of
**Dow Jones
Sustainability Indices**

Powered by the S&P Global CSA

Named to S&P Global
DJSI consecutively in
2021-2024



Joined the United Nations
Global Compact (UNGC)
in 2024



Listed in TIME's World's
Best Companies in
Sustainable Growth 2025



Awarded as Industry and
Regional Top-Rated company
consecutively in 2023-2024
by Sustainalytics



Named to FTSE4Good
Index consecutively in
2023-2024



Consecutive "A-" rating in CDP
Climate Change in 2022-2023,
first "A-" rating in CDP
Water Security in 2023

Unwavering Commitment to Customer IP Protection and the Highest Quality & Compliance Standards



404¹

Quality Audits & Inspections by Global Customers and Regulatory Authorities in H1 2024



38

Information Security Audits by Global Customers in H1 2024, with **0 Critical Findings**



100%

Pass Rate with **0 Critical Findings**



24²

Main Operating Sites are **ISO/IEC 27001 Certified**

9 Notes: 1. Including 351 audits by customers and 53 inspections by regulatory authorities.

2. Including all the main operating sites in China.

2. Business Highlights

Integrated Research Platform with WuXi Chemistry, WuXi Biology & WuXi Testing in Collaboration to Enable Innovation from Early Discovery Stage

WuXi Chemistry - Drug Discovery



Design

Discover Targets



Analyze

Develop & Run Assays



Deliver PCC¹

Demonstrate Efficacy



Enable IND¹


Prepare for FIH¹ Study



WuXi Biology

WuXi Testing - Lab Testing


Generate the Flow
by enabling discovery & research




Understand the Trends
by following science & customers




Achieve Synergy
through PCC¹ & IND¹




Building Capability at Innovation Forefront and Enabling CRDMO Business Model



of Compounds Delivered by WuXi Chemistry - Drug Discovery¹



Continue to Generate Downstream Opportunities and Achieve Synergy




of IND projects jointly supported by Discovery + Preclinical² platforms



¹² Notes: 1. Small molecule compounds successfully synthesized and delivered in the past 12 months.
2. Discovery represents WuXi Chemistry - Drug Discovery and WuXi Biology; Preclinical represents WuXi Testing - Lab Testing.

WuXi Chemistry: Growing Small Molecule CRDMO Pipeline Driven by “Follow the Molecule + Win the Molecule” Strategies



¹³ Notes: 1. Compounds successfully synthesized and delivered in lab over the 12 months ended September, 2024.

2. Molecules successfully moved to next stage in WuXi Chemistry in Q1-Q3 2024.


3. Small molecule D&M pipeline as of Q3 2024.

Small Molecule D&M: Expansion of Phase III & Commercial Pipeline Continues to Drive Strong Growth

of Small Molecule Phase III & Commercial Drugs


of Molecules

■ Phase III
■ Commercial



Revenue from Small Molecule Phase III & Commercial Drugs¹

RMB Billion



Produce 4 out of 10 Best-selling Small Molecule Drugs in 2023




4 out of 10

\$30+ billion

combined global sales of these 4 drugs in 2023

Produce 6 out of 31 Small Molecules Approved by US FDA in 2024

US FDA New Drug Approvals by Modality (2024)



6 out of 31

Produced **19%** of new drugs approved in 2024




Producing the Industry's Most Impactful New Therapies

7 OUT OF **10** *2023 Molecules of the Year Nominees*

“We asked our readers and reviewers to nominate molecules for our annual *Molecule of the Year* spot based on what you found most technically impressive and impactful. These top 10 finalists are selected based on technical achievement, scientific contribution, potential clinical impact, and originality.” — Drug Hunter

Capturing Fast Growing Glucagon-Like Peptide-1 Agonists (GLP-1) Market

WuXi Chemistry GLP-1 Pipeline Growth is Outpacing the Industry



Global clinical stage GLP-1 synthetic drug pipeline (small molecule & peptide) grew from 62 to 85 (+37% YoY) in 2024


WuXi Chemistry clinical stage GLP-1 drug pipeline grew from 13 to 20 (+54% YoY) in 2024

Estimated global sales of GLP-1 drugs in 2030 will reach **\$126B**, **3.4x** of the sales in 2023

TIDES (Oligo & Peptide): Enhancing Capabilities and Fast Growing Capacity to Bring the Next Wave of Accelerated Growth


TIDES Revenue

RMB Billion



Solid Phase Peptide Synthesizer Total Reactor Volume

Liter




3. Financial Performance

Navigating Through Cycles with Continued Growth in Revenue and Profitability

Revenue

RMB Billion


- Excluding COVID-19 Commercial Project
- COVID-19 Commercial Project



Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company

RMB Billion

- Adjusted Non-IFRS NPM%




Boosting D&M Orders and Enhancing Future Growth Visibility Through CRDMO

Total Backlog Growing 35% CAGR 2018-Q3 2024, with D&M Backlog Surging at 55% CAGR; 2x “R” Orders Amplified to 12x “D&M” Orders in the Same Period

RMB Billion


- Backlog excluding COVID-19 Commercial Project
- ▤ COVID-19 Commercial Project



Sustained Positive Free Cash Flow Driven by Business Growth and Operating Efficiency Improvement

Continued Strong Operating Cash Flow to Invest in Capabilities & Capacity & Talents; D&M Capex to Double in 2025


RMB Billion



Enabling Value Creation and Consistent Shareholder Returns

Basic Earnings per Share (EPS)¹ Continue to Improve Through Cycles


RMB



Dividends & Share Buybacks ~70% of Adjusted Non-IFRS Net Profit in 2024

RMB Billion

■ Dividends Declared & Paid
■ Share Buybacks for Cancellation



4. Growth Outlook

Our Unique CRDMO Business Model Positions the Company to Continue Growth in Both Good and Challenging Times



1

Our unique integrated CRDMO business model can effectively meet the growing demand of customers worldwide. It enables the Company to closely follow scientific innovations, develop distinct industry insights, instantly seize opportunities in new molecules as they rise, and **continue to drive solid business growth**

2

Despite uncertainties in the external environment, **revenue expects to reach RMB 38.3-40.5 billion in 2024, and maintain positive growth of 2.7-8.6% excluding COVID-19 commercial project**

3

Continue to improve operating efficiency. **Adjusted non-IFRS NPM in 2024 expects to remain at a similar level as last year**, taking into consideration of new capacity ramp-up and FX impact

4

Continue to expand global capacity, and constantly improve asset utilization & operating efficiency. **Free cash flow expects to reach RMB 6-7 billion in 2024** (with capex of RMB ~4 billion), which will **continuously cover investments in talents, cash dividends and share buybacks**

Disclaimer: This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not historical facts, but instead are predictions about future events based on our beliefs, development strategy, business plan as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect.